Quarterly Update – Q4 23 Test Volumes Reach New Record

INSIDE
Letter from the CEO 02
Test volumes rise to a new record 03
Triage gains CMS coverage 04
Annual meeting: save the date 04
Kaiser integration progress 05
Israeli distribution agreement signed 06
Standing room only at SESAUA 06
New study microDRIVE launched 07
APAC President appointed 08
Profile: Dr Daniel Shoskes 09
APRIL 23

PACIFIC EDGE LIMITED INVESTOR UPDATE | APRIL 2023
2
Dear Shareholders,
The close of the March 2023 quarter
represents the completion of my
first full financial year leading Pacific
Edge. While we are still seeking
clarity over continued Medicare
coverage of our tests in the US, I am
pleased to share my sense of pride
with what we have achieved.
Throughout the year we have
laid the foundations for success and
resilience in the US by executing
on the strategic pillars outlined a
year ago 1) the adoption and more
frequent use of Cxbladder tests;
2) generating clinical evidence to
support Cxbladder coverage and
their inclusion in global standards
of care; and 3) continued innovation
over the long term.
Steady quarter-on-quarter
improvements have continued in the
final three months of FY23.
The volume of tests processed
in our laboratories reached a record
8,878 in the quarter (Q4 23) – a 14%
increase on the prior quarter (Q3
23) and up 42% on the same quarter
a year ago (Q4 22).
The result brings total testing
volumes for FY 23 to 31,566 – a 37%
uplift on FY 22’s 23,086 tests. The
number of US ordering clinicians has
also continued to rise (see page 3).
At the start of the third quarter,
Cxbladder Triage received a CPT
1

code and was added to the Novitas
Local Coverage Article (LCA 58917)
which Pacific Edge relies upon for
Medicare coverage for all our tests
in the US.
This development recognizes
that Triage now is covered subject
to medical necessity in the same
manner as Detect and Monitor.
Consequently, we expect it to
drive a modest improvement in
payment recoveries from Medicare
and Medicare Advantage payors.
However, we do not expect it to
drive a significant uplift in usage
of Triage in the US as we focus our
efforts on Detect
+
(see page 4).
The approach of gaining a
CPT code and the inclusion in the
LCA58917 also potentially offers
a faster and tangible path for
coverage for our new test Cxbladder
Detect
+
, assuming of course the
current or similar approach to
US reimbursement of our tests is
retained.
The integration of Cxbladder
into the Electronic Medical Records
system of our largest customer
Kaiser Permanente, has progressed,
but not as fast as we expected. The
development teams on both sides
have now completed the software
development and integration
testing, however, due to the
substantial nature of the integration
into a live system at Kaiser,
additional administrative and review
processes remain to be completed
(see page 5).
Despite these recently added
administrative requirements, the
Kaiser urologists, the innovation
group, the EMR implementation
team and the Pacific Edge team
continue to share a common goal
and a common commitment to
completion as soon as feasible.
Our evidence generation
program continues to evolve,
particularly in furtherance
of achieving guidelines
recommendations. Notably we have
launched a new study with the VA,
we have called microDRIVE, which in
combination with existing studies is
aimed at demonstrating the clinical
validity of Cxbladder Detect
+
in
detecting bladder cancer in patients
presenting with microhematuria.
Independent studies on the utility
of Cxbladder products meanwhile
continue to support the evidence
we gain from our own program (see
page 7 and 8).
Late in the quarter, we signed
a distribution agreement for
Cxbladder in Israel with the Tel
Aviv-based company ProGenetics as
we consider global markets with an
appetite for genomic oncology tests
that can be sent to our US Lab (see
page 6).
Finally, we continue to build
capability in the leadership team.
In this update we profile two new
members, Glen Costin who has
been appointed as our new APAC
President (page 8) and Dr Daniel
Shoskes, who joined a few months
ago as a Medical Director in our
Medical Affairs team.
Our focus now is firmly on
execution. We look forward to
updating shareholders on our
progress when we release our 2023
financial results in late May.
Ngā mihi,
Dr Peter Meintjes
Chief Executive
LETTER FROM THE CEO
A YEAR OF STEADY
STRATEGIC PROGRESS
1
Current Procedural Terminology code: a set of medical codes created and maintained by the American Medical Association that are used to describe medical, surgical,
and diagnostic services performed by healthcare providers in the United States.

UNIQUE ORDERING CLINICIANS: US
2
-
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
Q1 23Q2 23Q4 22Q3 22Q2 22Q1 22Q4 21Q3 21Q2 21Q1 21
Test volume
USNZ
2,791
3,110
3,824
4,277
4,706
4,591
5,290
6,073
6,699
1,073
1,079
1,074
1,117
952
983
1,165
Q3 23Q4 23
6,629
1,139
7,817
1,061
943
1,088
2,133
852
35%
CAGR
TOTAL TEST VOLUMES: GROUP
PACIFIC EDGE LIMITED INVESTOR UPDATE | APRIL 2023
3
TEST
VOLUMES
TEST VOLUMES RISE TO A NEW RECORD
Test volumes processed at Pacific Edge laboratories rose to a new record in the fourth quarter of the 2023
financial year (Q4 23) rising to 8,878 tests, a 14% rise on the 7,768 tests in the prior quarter (Q3 23).
The volume processed in Q4 23 represents a 42% incre
ase on the 6,242 tests processed in the same quarter of
the prior year (Q4 22). The result brings total volumes for FY 23 to 31,566 – a 37% increase on the 23,086 tests in the
prior financial year (FY 22).
US volumes led the growth
rising to 7,817 in Q4 23, an 18% increase on the 6,629 tests in Q3 23. The figure also
represents a 48% increase on the 5,290 tests processed in Q4 22. The result brings US test volumes for FY 23 to
27,2
18, an increase of 44% on the 18,864 in FY 22.
The number of unique ordering clinicians in the US has continued to grow through the quarter to 1,151 at the end
of Q4 23, up 6% on the 1,081 ordering in Q3 23 and up 46% on the 789 clinicians who ordered tests in Q4 22.
A
sia Pacific volumes in Q4 23 were 1,061 down 7% on the 1,139 tests processed in Q3 23, but up 11% on the 952
tests processed in Q4 22. Total APAC volumes for FY 23 were 4,348, a 3% increase on the 4,222 tests processed in
FY 22. The volume trends in APAC reflect the maturity of the New Zealand market and the region’s ongoing
h
ealthcare reforms.
2
Historic numbers of unique ordering clinicians in the US have changed slightly, correcting data recording inconsistencies determined by ongoing data provenance initiatives.
-
200
400
600
800
1,000
1,200
Q1 23Q2 23Q4 22Q3 22Q2 22Q1 22Q4 21Q3 21
Physicians
47%
CAGR
515
530
Q2 21Q1 21
411
462
657
690
741
789
895
980
Q3 23Q4 23
1,081
1,151

PACIFIC EDGE LIMITED INVESTOR UPDATE | APRIL 2023
4
MEDICARE COVERAGE
CXBLADDER TRIAGE GAINS
MEDICARE COVERAGE
SAVE THE DATE
CONNECT WITH
US AT OUR
2023 ANNUAL
MEETING
Pacific Edge’s 2023 Annual
Shareholders Meeting will this year
be held in Auckland and we will be
using it to connect shareholders
with the strategies we are using to
drive the success of Cxbladder in the
US market.
Pacific Edge Diagnostics USA
President David Levison and
VP of Medical Affairs, Dr Tamer
Aboushwareb, who are both on the
frontline of driving the adoption of
Cxbladder, will address the meeting
and take shareholder questions.
As usual our directors and senior
management will also be present to
meet shareholders. All shareholders
unable to join in person in Auckland
will be able to join virtually. More
detail on the meeting will be released
with the publication of our Annual
Report.
Where:

Link Mark
et Services
Board Room
Level 30, PwC Tower
15 Cus
toms Street West
A
uckland 1010
When:
3:00pm 2
7 July 2023
Connect virtually:
www.virtualmeeting.co.nz/peb23
3
Novitas has a policy of covering products on LCA 58917 under the 21st Century Cures Act, if
clinicians deem the tests medically necessary, until the publication of an LCD either covering or
denying coverage of a product.
4
Current Procedural Terminology code is a set of medical codes created and maintained by the
American Medical Association that are used to describe medical, surgical, and diagnostic services
performed by healthcare providers in the United States.
5
Lotan et al ‘Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of
Cxbladder Tests and Improves Patient Risk Stratification’ J Urol. 2023 Apr; 209 (4): 762-772.
Cxbladder Triage, our test to assist clinicians to safely de-
intensify hematuria evaluation in populations with a low
incidence of bladder cancer, has now been included in the
Local Coverage Article (LCA 58917) that Pacific Edge currently
relies upon for Medicare coverage of all our tests in the US.
3
Novitas, the Medicare Administrative Contractor with
jurisdiction for Pacific Edge’s US laboratory, listed Triage in
its LCA in January as a test covered with medical necessity. It
follows the issuing of a CPT
4
code (0363U) in the third quarter
of the financial year.
We expect the development to lead to modest increases
in rates of payment from Medicare and Medicare Advantage
payors for Triage. We also see coding and listing in LCA 58917
as a faster more tangible path for our enhanced test Cxbladder
Detect
+
to gain coverage, should the current approach to
reimbursement of our tests in the US continue.
“We expect the development to lead to modest
increases in rates of payment from Medicare and
Medicare Advantage payors for Triage.”
T
hat said, we do not expect the development to drive a
significant increase in adoption of Triage in the US. Triage
currently makes up a small fraction of commercial testing
volume in the US outside of those contracted by our largest
US customer Kaiser Permanente. Triage also still needs a price,
established by Medicare through the national pricing process,
which will make reimbursement more reliable and timely by
Medicare and Medicare Advantage payors around the US.
Finally, going forward in the medium term, Pacific Edge plans
to promote Cxbladder Detect
+
rather than the existing Triage
test as the best test for risk stratification and de-intensifying
hematuria evaluation. This new approach follows the publication
in December
5
of clinical evidence that demonstrated the superior
performance of Detect
+
.
We also acknowledge the potential for Cxbladder Triage
to lose its coverage in the same way as Detect and Monitor if
a proposed Local Coverage Determination governing Genetic
Testing for Oncology (DL39365) were to be finalized without
changes and without addressing the comments and concerns
from Pacific Edge.
Novitas put forward DL39365 in July 2022, and must either
finalize or withdraw it within 12 months of the date of the
proposal.

PACIFIC EDGE LIMITED INVESTOR UPDATE | APRIL 2023
5
STRATEGIC ACCOUNTS
KAISER EMR INTEGRATION
TECHNOLOGICALLY COMPLETE
Pacific Edge has now completed
the software development
and integration testing on its
project to integrate Cxbladder
into the Electronic Medical
Records (EMR) system of Kaiser
Permanente. We continue to
complete the administrative
and review processes required
to be a registered supplier to
Kaiser Permanente to enable the
project to go live.
We are excited to have
achieved the important technical
milestones in the project, which
has spanned many teams and
many person-hours across
the Kaiser system, our team in
the US, and our team in New
Zealand.
We have significantly
de-risked the project and
importantly, the Kaiser urologists,
innovation group, EMR
implementation team and Pacific
Edge team continue to share a
common goal and a common
commitment to completion as
soon as feasible.
“Cxbladder tests have
improved access to
urology care as Kaiser
has emerged from the
pandemic.”
K
aiser Permanente Southern
California Permanente Medical
Group urologist Dr Ronald
Loo, MD, says the Cxbladder
tests have improved access
to urology care as Kaiser has
emerged from the pandemic
with unprecedented demand for
services.
“The very high negative
predictive value of the
Cxbladder tests have allowed
us to improve access by safely
reducing overwhelming demand
for screening and surveillance
cystoscopy. It’s proven to be a
quadruple win: convenient and
preferred by our members, high
quality - reliable results, cost
effective for the organization,
and a sustainable way to improve
the wellbeing of our healthcare
teams,” Dr Loo said.
Kaiser Permanente is
the largest integrated
healthcare provider in the
US, serving 12.6 million
members, which equates
to approximately 3.7% of
the population in the USA.
It operates 39 hospitals,
more than 700 medical
offices, and employs
23,656 physicians and
65,000 nurses.

PACIFIC EDGE LIMITED INVESTOR UPDATE | OCTOBER 2022
6
NEW MARKET
ISRAELI
DISTRIBUTOR
FOR CXBLADDER
APPOINTED
CONFERENCES
STANDING ROOM ONLY AT
CXBLADDER SYMPOSIUM
A Pacific Edge symposium on the use of molecular
biomarkers in the detection and surveillance of bladder
cancer drew strong interest at the 87th American Urological
Association Southeastern Section (SESAUA) conference held
in Amelia Island, Florida last month.
The conference is one of the largest AUA Section Meetings.
It has a strong research focus and it offered time before the
conference program to hold a Principal Investigator meeting
for our STRATA clinical trial.
Additionally, Pacific Edge hosted a symposium in which
more than 100 urologists and urological experts participated.
Many were left standing for the keynote address from Dr.
Sia Daneshmand, Professor of Urology and Director of Clinical
Research at the Keck School of Medicine, and the discussion
that followed..
Pacific Edge VP of Medical Affairs, Dr Tamer Aboushwareb,
who led the symposium, said he was delighted with the
interest in Cxbladder at the conference.
“We were thrilled to see so many attendees at the
symposium showing great interest in the utility of Cxbladder.
Many more physicians identified the utility of the tests and
showed interest in using them in their patient populations; they
will all be followed up by Pacific Edge’s sales team,” he said.
At the conference, alongside the symposium, Pacific Edge
led a Principal Investigator meeting (IM) for the DRIVE study
– which is focused on Cxbladder Detect
+
validation across
multiple Veterans Administration sites.
The team also held multiple meetings with key opinion
leaders from the SESAUA with many continuing or starting the
use of Cxbladder in their respective organizations.
As Pacific Edge looks to develop Ex-
US commercial activity from Pacific
Edge Diagnostics USA (PEDUSA),
ProGenetics in Israel is the first
distributor with the resources and
expertise to join our distributor
network. The Tel Aviv-based
company has been awarded exclusive
sales and marketing rights in Israel
and will add Cxbladder to its broad
portfolio of the cancer diagnostic
tools it distributes. These tests span
tests for breast, prostate, ovarian, and
colon cancers among several others.
David Sosa, Pacific Edge’s VP
Market Access & Reimbursement
says: “We are delighted to be working
with a company that has such a
strong record of launching high-value
lab developed tests and working
with local healthcare plans to achieve
reimbursement. ProGenetics will drive
the integration of Cxbladder into
local standards of care leveraging its
strong relationships with clinicians,
and Pacific Edge’s growing body of
clinical evidence.”
Initially, the tests will be paid for
by patients on the recommendation
of their clinicians. Patient samples
will be collected using Pacific Edge’s
Patient In-Home Sampling System
and will be processed at our US
laboratory in Hershey Pennsylvania.
PEDUSA will support ProGenetics
with its Medical Affairs team and
provide training in sample collection
and logistics.

PACIFIC EDGE LIMITED INVESTOR UPDATE | APRIL 2023
7
RESEARCH AND INNOVATION
NEW STUDY TO VALIDATE CXBLADDER WITH
MICROHEMATURIA
Pacific Edge is launching a new study to demonstrate the validity of its new test, Cxbladder Detect
+
,
in detecting urothelial cancer in patients presenting with microhematuria.
The new study is microDRIVE - Detection and Risk Stratification in Veterans Presenting with microhematuria.
Microhematuria is a presentation of blood in urine that is not detectable with the naked eye. It is often found
in routine testing rather than the result of examinations related to symptoms that are potentially indicative of
bladder cancer.
MicroDRIVE will compare the performance of Detect
+
against the current gold-standard for the detection of
urothelial cancer, diagnostic cystoscopy and pathology. It runs alongside the existing DRIVE study with the VA.
The study is seeking to recruit up to 1,000 veterans and is projected to start recruitment towards the end of 2023,
with the aim of recruiting the last patient in the second quarter of 2024.
ONGOING STUDY PROGRAM ENROLLED SITES
AND LOCATIONS
PROGRESS AND TARGETS*
STRATA
(Safe Testing of Risk for Asymptomatic
Microhematuria)
11/13
USA and Canada
-
Enr
olment total is 468, including 122 ‘low risk’
subjects (with 400 and 105 of these subjects
eligible, respectively) that are the focus of the study
-
T
arget ~600 subjects, including 120 low risk subjects
randomized to test arm
-
Las
t patient in Q2 2023
-
F
ollow up until Q2 2024
DRIVE
(Detection and Risk Stratification in
Veterans Presenting with Hematuria)
8/11 (VA)
USA
-
Enr
olment total is 551
-
T
arget (Q2 2025) ~700 patients
-
Last patient in: Q3 2023
-Follow up: until Q3 2025
microDRIVE
(Detection and Risk Stratification in
Veterans Presenting with microhematuria)
0/0
USA
-
Pr
ojected to start recruitment Sep/Oct 2023
-
T
arget is 1000 patients
-
Las
t patient in: March/April 2024
AUSSIE
(Australian Urologic risk Stratification of
patients with hematuria)
1/1
Australia
-
C
ontract fully executed Mar 2023
-
Enrolment due to start in Q2 2023
-
Las
t patient in: Q2 2025
DEDUCT
(Detection of Disease in the Upper Tract)
-Now to be transferred to an investigator-initiated
study
LOBSTER
(Longitudinal Bladder Cancer Study for
Tumor Recurrence)
3/11
-
T
hree sites are open and another 8 are at pre-
activation. Enrolment is now 63 patients
-
Each site will enroll 100 patients within 12 months
and follow up for another 12 months
MONSTER
(Monitoring
Study of Post-Treatment
Effectiveness for Residual Disease)
0/1
New Zealand
-
Finalizing pr
otocol documentation and commenced
engagement with ethics committee
-
Busines
s case for this study currently in
development by R&D
*Dates are calendar year not financial years
Analytical Validity: Develop a test that is repeatable in the lab for a given indication and population.
Clinical Validity: Make sure the test works in the same way on an independent eligible population for the given indication.
Clinical Utility: Put the test in the hands of a physician to establish that it can usefully change patient management within
the context of care for the defined population and indication.
Visit the Pacific Edge website to learn more about the strategic rationale for our studies.

PACIFIC EDGE LIMITED INVESTOR UPDATE | APRIL 2023
8
RESEARCH AND INNOVATION
STUDY ADDS SUPPORT FOR
CXBLADDER MONITOR USE IN
CANCER SURVEILLANCE
ASIA PACIFIC
NEW APAC LEADER
Glen Costin has been appointed
into the new role of President
Asia Pacific (APAC) to realize
the significant potential for the
company’s genomic Cxbladder tests
in the region.
Glen is charged with building on
our presence in Australia and New
Zealand into the broader APAC
region. He will drive the strategic
and operational direction in the
region, which boasts an estimated
total addressable market for the
company’s Cxbladder diagnostic
tests of US$2.2 billion.
8

For the last eight years, at the
helm of his own company MDL Asia,
Glen has assisted small and medium
sized medical, diagnostics and life
science companies to expand in the
Asia Pacific. Over that period, he
assisted his clients to grow annual
revenues by US$20 million to US$30
million per year. Prior to that he
held senior roles with biotechnology
research company Abcam,
laboratory equipment supplier Bio-
Rad Laboratories and BD (Becton
Dickinson).
He brings to Pacific Edge a
strong regional network in APAC, a
strong commercial background, a
track record of success in business
development and in bringing new
technology to market. He holds a BSc
from Macquarie University and an
MBA from the Macquarie Graduate
School of Management. He started at
Pacific Edge on March 27th and will
report to Dr Meintjes.
8
Pacific Edge estimates.
6
The study, “Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder
cancer”, was completed with no involvement or financial support from PEDUSA
7
Six of the 66 CxbM negative patients did not return for a follow up cystoscopy, four elected to
undergo a further CxbM test rather than a cystoscopy and the remaining four patients either stopped
surveillance or died of unrelated causes. Nine of the 24 patients that tested Cxbladder Monitor
positive and then had an immediate clinical evaluation and cystoscopy were found to have cancer
including one patient that had cancer in the upper tract.
New and independent
6
research supporting the clinical utility
of the company’s genomic biomarker test Cxbladder Monitor
in the surveillance for bladder cancer recurrence is to be
published in the prestigious journal Urologic Oncology.
The study undertaken at the University of California San
Francisco (UCSF) and the University of Michigan examined
whether a negative Cxbladder Monitor test could safely
postpone a patient’s next scheduled cystoscopy, the current
‘gold standard’ for bladder cancer surveillance.
The study covered a small sample of US-based patients
under surveillance for bladder cancer recurrence during the
COVID pandemic lockdown. The patients - under the virtual
supervision of their clinicians - opted to use Cxbladder Monitor
leveraging Pacific Edge’s Patient In-Home Sampling System
(PIHSS) as a first step to overcome pandemic-related limits on
clinical evaluation slots and the risks of COVID infection during
travel to and from appointments.
Of the sample, 66 patients tested negative for Cxbladder
Monitor. Of those, 52 patients underwent a follow up
cystoscopy, and all were tumor free – a result that supports
the growing portfolio of evidence that Cxbladder Monitor can
safely reduce surveillance cystoscopies without compromising
cancer detection.
7
Meanwhile, a patient satisfaction survey of
those who took the Cxbladder Monitor test at UCSF revealed
strong patient acceptance for the test and the PIHSS.
Vice President of Medical Affairs Dr Tamer Aboushwareb
said: “The sample size and the difficulties the researchers faced
in following up all those patients that tested Cxbladder Monitor
negative represent obvious limitations to the current study, but
the results represent an exciting incremental addition to the
evidence supporting the clinical utility of Cxbladder Monitor in
safely reducing the frequency of surveillance cystoscopy.”
University of California San Francisco

PACIFIC EDGE PEOPLE
JOINING THE COMPANY WITH THE MOST DATA
Dr Daniel Shoskes joined Pacific Edge Diagnostics USA at the end of October as Senior Medical Director. In
his role as part of Pacific Edge’s Medical Affairs team Daniel will be focused on our education mission.
He is also tasked with encouraging research into Cxbladder through the development of a program to support
investigator-initiated trials as well as new registries to accumulate real world data on the use of Cxbladder.
Daniel joins Pacific Edge as a well-known member of the urological community with a wealth of experience. He
has worked as an academic Urologist at UCLA and the Cleveland Clinic and has held several roles at the American
Urological Association (AUA), including the presidency of two sub-specialty societies, and directorship of the AUA
Board Review Course. Daniel has also served on both the AUA Research and Education Councils.
What brings you to Pacific Edge?
Pacific Edge VP Medical Affairs Dr Tamer Aboushwareb was a colleague
at Exact Sciences where we worked on prostate cancer diagnostic tests,
and I knew we worked together well. Additionally, it was attractive to join
the company with the most data to date and a growing list of new studies
poised to generate evidence that should be compelling to the committees
setting clinical guidelines. .
What is the most compelling evidence in your view supporting the use of
Cxbladder?
I think there are two distinct and complementary perspectives supporting
the use of Cxbladder. From the patient’s point of view there is convenience
and reduction of anxiety. The ability to do a home test prior to scheduling
an appointment or procedure can save time and cost.
With a negative Cxbladder test there is confidence in avoiding an
uncomfortable procedure. From the Urologist point of view there is added
confidence in getting the diagnosis right and only escalating to more
invasive testing if it is warranted.
Not every hematuria patient presents with symptoms where the course of
action is clearly outlined by the guidelines. For example, there are patients
with benign causes of hematuria that don’t warrant treatment but whose
recurring hematuria technically leads to repeated cystoscopy. There are
patients whose cystoscopy is very challenging with the view obscured by
inflammation, bladder abnormalities, and other pathologies. In these cases,
adding Cxbladder to the diagnostic armamentarium can give confidence in
the diagnosis and simplify care.
What criteria will you use to judge success in your role at Pacific Edge?
In terms of new initiatives, I’m excited about our Investigator Initiated Trials
program and its ability to produce high quality publications that will further
the evidence for efficacy and utility of our products. On an incremental
level, I hope to refine our messaging of the value proposition for using
Cxbladder for Urologists and make it clearer which patient scenarios will
most benefit from adding Cxbladder to the workflow.
What will make the greatest difference to driving the adoption of
Cxbladder?
Being in clinical guidelines goes a long way to widespread clinical adoption
as well as robust insurance coverage (in the USA). I am confident that the
new clinical trials now in design and being carried out at Pacific Edge are
set up to deliver the kind of compelling validity and utility data that would
lead to guidelines adoption.
What is the newest addition to your Spotify playlist and why?
I deleted my Spotify account in response to their financial support of anti-
vaccine podcasts, but music is an important part of my life, both listening
and performing. While most of my performance has been in Renaissance
and Baroque music, I have recently started playing Medieval music on the
Gittern, a plucked instrument popular in the 12th to 15th centuries.
PACIFIC EDGE LIMITED INVESTOR UPDATE | APRIL 2023
9
DR DANIEL SHOSKES

Senior Medical Director
MD, MSc, FRCS (C)
1994 – 2000:
Urologist.
UCLA
2000 – 2005:
Urologist and Director of
Kidney Transplant Program.
Cleveland Clinic Florida
2005 – 2021:
Professor of Urology
, Director,
The Novick Centre for Clinical
and Translational Research;
Director The Center for Men’s
Health. Cleveland Clinic
2021 – 2022:
Medical Director Medical
Affairs.
Exact Sciences

ABOUT US
Pacific Edge Limited (NZX/ASX: PEB) is a
global cancer diagnostics company leading
the way in the development and
commercialization of bladder cancer
diagnostic and prognostic tests for patients
presenting with hematuria or surveillance of
recurrent disease. Headquartered in Dunedin,
New Zealand, the company provides its suite
of Cxbladder tests globally through its wholly
owned, and CLIA certified, laboratories in New
Zealand and the USA.
VISIT US ONLINE:
www.pacificedgedx.com
www.cxbladder.com
FOLLOW US ON SOCIAL MEDIA:
www.facebook.com/PacificEdgeLtd
www.facebook.com/Cxbladder
www.twitter.com/PacificEdgeLtd
www.twitter.com/Cxbladder
www.linkedin.com/company/pacific-edge-ltd
CONTACT US:
Centre for Innovation
87 St David Street
PO Box 56
Dunedin 9016, New Zealandd
T: +64 3 479 5800
E: investors@pacificedge.co.nz